NCT05873868Active, not recruiting
Myocardial Effects in Patients With ATTRv With Polyneuropathy Treated With Patisiran or Vutrisiran
MyocardON-TTR - Myocardial Effects in Patients With Hereditary Transthyretin-mediated Amyloidosis With Polyneuropathy Treated With Patisiran or Vutrisiran
Source: ClinicalTrials.gov · Last updated 5 Jan 2026
Brief summary (registry, in English)
ATTRv amyloidosis is a systemic disease with two clinical forms, neurological and cardiological, which are sometimes combined (so-called mixed forms). Patisiran and vutrisiran have shown protective effects on the progression of neurological damage. The effects of Patisiran or vutrisiran on the heart remain incompletely understood. The aim of this study is to better understand the morphological and functional cardiac consequences in ATTRv patients with stage 1 or 2 polyneuropathy with a mixed form treated with Patisiran or vutrisiran
- Status (registry)
- Active, not recruiting
- Study type
- Observational
- Enrollment
- 20 (estimated)
- First submitted
- 15 May 2023
- Start date
- 12 Apr 2024
- Primary completion date
- Dec 2027
- Lead sponsor
- Rennes University Hospital
- Diseases
- Amyloidosis
- NCT number
- NCT05873868
What you commit to
- Study type: Observational
- Planned participants: 20
- From 12 Apr 2024 to the primary completion date, Dec 2027
- 5 sites in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- Patients treated with Tafamidis simultaneously with patisiran or vutrisiran
Age
- Contraindications to the explorations provided for in the protocol: claustrophobia, metallic implant contraindicating MRI, woman of childbearing age
Other
- Adults under legal protection (legal guardianship, curatorship, guardianship), persons deprived of liberty.
Who the study is looking for
- Patients aged 18 years or older
- Patients with hereditary transthyretin amyloidosis (ATTRv) with stage 1 or 2 polyneuropathy
- Patient not previously treated for ATTRv
- Patients for whom treatment with patisiran or vutrisiran has been initiated by a hospital neurologist in accordance with recommendations for a minimum of 24 months.
- Patients with NYHA stage 1 and 2 cardiac disease.
- Beneficiary of a social security scheme
- Person who does not object to his/her participation in the research
Age in the registry: 18 years to - · Sex: All · Does not accept healthy volunteers
Sites (5)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| CHU Bordeaux Haut-Levêque Coordinator of this site? Confirm its status | Bordeaux | France | Unknown status |
| APHP Henri Mondor Coordinator of this site? Confirm its status | Créteil | France | Unknown status |
| CHU Grenoble Alpes Coordinator of this site? Confirm its status | Grenoble | France | Unknown status |
| CHU Nancy Institut Louis Mathieu Coordinator of this site? Confirm its status | Nancy | France | Unknown status |
| CHU Rangueil Toulouse Coordinator of this site? Confirm its status | Toulouse | France | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.